Research Antibodies Market Size, Share, Analysis and Forecast to 2028

The global research antibodies market size was estimated at USD 3.6 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.4% from 2021 to 2028.

The global Research Antibodies Market size is expected to reach USD 5.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.4% from 2021 to 2028. Major market drivers include a rise in R&D initiatives undertaken by biopharmaceutical and biotechnology companies and government bodies, an increase in neurobiology and stem cell research, availability of technologically advanced products, and strategic collaborations among various key players.

An increase in the usage of research antibodies to develop therapies for various chronic and infectious diseases, including COVID-19, is anticipated to boost the market growth during the forecast period. For instance, in June 2019, the Institute of Life Sciences (ILS, India) developed antibodies against chikungunya viral infection. These antibody structures were developed to aid scientists in understanding various aspects of virus pathogenesis entailing further research on antiviral therapies. Growing government funds and initiatives for R&D are anticipated to fuel market growth during the forecast period in the Asia Pacific region. According to the 2018-2019 Australian Budget, approximately USD 94 million was estimated for four years for new industry collaborations, research as well as new biomedical and medical programs.

Additionally, a rise in funds invested by pharmaceutical and biotechnology companies to enhance proteomics and genomics research is expected to boost market growth. For instance, in 2017, Biognosys Inc. raised USD 5 million in funds to increase, advance, and develop next-generation proteomics products and workflow for high throughput and high content protein analysis. The rise in the number of major players investing in advanced technologies and collaborating with other key players is also anticipated to impact market potential positively in the near future. For instance, Abcellera uses technologically advanced techniques to test antibodies from single B cells, map and screen natural immune responses, and discover novel antibody therapies. The company has also partnered with Sanofi, Pfizer, Teva, Merck, and GSK to discover and develop new antibody-based therapies. Moreover, the launch of novel antibody structures for the diagnosis of various diseases is also a major factor expected to boost market growth. For instance, in August 2018, BioGenex launched a range of new antibodies for its use in cancer immunohistochemistry.

Related Press Release@ Research Antibodies Market Report

Research Antibodies Market Report Highlights

• In 2020, primary antibodies held a dominant share in terms of revenue in the product segment owing to greater specificity, therefore, leading to increase adoption in R&D activities        
• Monoclonal antibodies captured a substantial share in 2020, as they offer higher sensitivity for the detection of antigens and also showcase efficient staining properties for various applications
• The neurobiology segment is expected to witness exponential growth over the forecast period owing to the increasing prevalence of diseases that have limited treatment options and the rise in R&D activities by biotech companies and academic institutes
• Pharmaceutical and biotechnology companies were dominant in terms of revenue amongst all end-users in 2020, owing to the increased adoption of research antibodies in drug development and discovery
• In 2020, North America accounted for the substantial revenue share which is attributable to the high presence of many biotechnologies as well as biopharmaceutical manufacturers, research academies, and laboratories